Zinc and copper concentrations in leucocytes and erythrocytes in healthy adults and the effect of oral contraceptives

LESLEY J HINKS, BARBARA E CLAYTON, RS LLOYD

From the Department of Chemical Pathology and Human Metabolism and the Professorial Medical Unit, Medical Faculty of the University of Southampton, Southampton General Hospital, Southampton

SUMMARY The content of zinc and copper of whole blood, plasma, erythrocytes and white cells, has been measured in normal controls. The concentrations of zinc and copper in leucocytes are about seven and ten times respectively higher than those in erythrocytes. Women taking oral contraceptives showed significant increases in the concentrations of copper in plasma and whole blood but not in leucocytes or erythrocytes. Oral contraceptives did not alter the concentration of zinc in any of the fractions or in whole blood. These data provide a baseline for the assessment of the body status of zinc and copper in various disease states in which deficiencies may be present.

Zinc and copper are two of the most intensively investigated essential trace elements but none of the methods currently used to assess their body status is ideal. Attempts to determine body zinc and copper status from the concentrations of zinc and copper in biological tissues and fluids such as plasma, serum, whole blood, urine, hair, saliva, fingernail, and skin have been shown to be generally inadequate for diagnostic purposes. Elemental concentrations in plasma or serum are the most widely used indices of copper and zinc nutrition, but their circulating concentrations may be increased or decreased by many factors. Oestrogens, corticosteroids, and stress situations including infections, influence the production or release of caeruloplasmin which contains more than 90% of the copper circulating in plasma. The total circulating concentrations of zinc in serum are dependent on both serum albumin concentration and the affinity of albumin for zinc. Approximately 80% of the circulating zinc is bound loosely to albumin and approximately 20% is tightly bound to alpha-2-macroglobulin. Erythrocytes and leucocytes are components of haemopoietic tissue which are readily accessible for biochemical analysis. Measurements of copper and zinc in erythrocytes may be useful for indicating long-term zinc and copper status since these cells have an average life-span of 110 days. The analysis of leucocytes may reflect more accurately acute changes in zinc and copper status as these are metabolically more active and have a shorter life span than erythrocytes, and because they (unlike erythrocytes) are nucleated, they are more likely to be representative of other cells. It has been demonstrated that leucocyte zinc can be lowered by experimental zinc deficiency in man and reduced leucocyte zinc concentrations have been reported in patients with liver disease, indicating a possible tissue zinc deficiency.

The present study was undertaken to investigate the concentrations of zinc and copper in whole blood, plasma, erythrocytes and leucocytes of normal human subjects, in order to provide control data for use in studies of metabolic disorders that may involve copper and zinc.

Patients, material and methods

SUBJECTS Whole blood was obtained from 119 normal healthy volunteers: 55 men aged 18–63 yr and 64 women aged 21–57 yr. Of the women who participated, 22 were regularly taking combination type (ethinyl-oestradiol 30 µg, levonorgestrel 150 µg) oral contraceptives (“the pill”).

SAMPLES Samples (19 ml) of venous blood were collected between 0900 and 1100 h and the sample was sub-divided in the following way: 15 ml was transferred to a siliconised glass tube for leucocyte separation;

Accepted for publication 20 April 1983
Zinc and copper concentrations in leucocytes and erythrocytes in healthy adults

2 ml was added to a trace-metal-free tube containing heparin for erythrocyte and plasma separation; the remaining 2 ml was added to a trace-metal-free tube containing EDTA for the determination of full blood count, packed cell volume and whole blood copper and zinc determination.

**Leucocyte separation and analysis**
Leucocytes were separated and analysed for copper and zinc content as previously described.7

**Plasma analysis**
Plasma was analysed for copper and zinc by a modified version of the method of Meret and Henkin.8 Within and between-batch precisions were: 2-4% and 3-1% for zinc at 15-5 μmol/l; and 2-8% and 3-9% for copper at 17-5 μmol/l.

**Erythrocyte separation**
The red blood cells obtained from the heparinised blood samples were washed three times with 0-9% saline. After the last wash, a volume of saline approximately equal to the volume of red blood cells was added.

**Cell counting**
Red blood cell counts were determined on the whole blood and red cell suspensions using a Coulter Counter, Model DN, in conjunction with the Coulter Dual Dilutor III.

**Haematocrit measurement**
Haematocrit measurements were made with a microhaematocrit centrifuge (Hawksley), spinning at 13 000 g for 5 min.

---

**ANALYSIS OF COPPER AND ZINC IN WHOLE BLOOD AND ERYTHROCYTES**
Before copper and zinc analysis the samples were frozen at −20°C. Thawing produced complete haemolysis of the red blood cells and homogeneous samples were obtained after dilution.

**Reagents**
All reagents were obtained from BDH Chemicals Ltd, Poole, Dorset.
Zinc chloride standard solution, 5 mmol/l of zinc.
Copper (II) chloride standard solution, 5 mmol/l of copper.
Triton X-100, 0-01% vol/vol aqueous solution.
Butan-1-ol, “Aristar” grade 6% vol/vol aqueous solution.
Water, deionised distilled water was used throughout.

**Instrumentation**
A Perkin-Elmer 560 atomic absorption spectrophotometer was used for the measurement of copper and zinc by atomic absorption spectrophotometry using an air-acetylene flame.

**Glassware**
All glassware was first cleaned with 5% vol/vol Decon 75 solution, then soaked in 10% vol/vol nitric acid for approximately 12 h, followed by six rinses with deionised distilled water.

**Stock blood sample**
A stock sample of whole blood was obtained by venepuncture from a healthy adult and the blood was transferred to and stored at −20°C in a series of 2 ml volume trace-metal-free tubes (Teklab Ltd, Durham). A further sample of whole blood was taken to provide a stock suspension of red blood cells and aliquots of this were also stored at −20°C.

**Analysis of zinc**
The stock zinc standard solution was diluted with deionised water to give working standards containing 0, 50, 100 and 150 μmol/l of zinc. A calibration graph was prepared using 40 μl of working standard + 40 μl of the stock blood sample + 1 ml of butanol to give a 1 + 26 dilution. Samples of whole blood (40 μl) were added to 40 μl of water and 1 ml of butanol. Samples and standards were then directly aspirated into the flame. No physical interferences from viscosity or surface tension of the blood matrix were observed at this dilution. The zinc concentrations of red blood cell suspensions were similarly determined, except that the stock red blood cell suspension was used for preparing the calibration graph. This method gave a within batch RSD and a between batch RSD of 1-3% and 2-1% respectively at a concentration of 114 μmol/l of zinc.

**Analysis of copper**
The stock copper standard solution was diluted to give working standards of 0, 5, 10, 20, 30 and 40 μmol/l of copper. A calibration graph was prepared by diluting 100 μl volumes of the stock blood sample 1 + 1 + 1 with Triton X-100 solution and each of the series of working standard solutions. Duplicate samples of whole blood (100 μl) were prepared for analysis by diluting with 100 μl water and 100 μl Triton X-100 solution. Diluted standards and samples were introduced into the flame by means of a PTFE “small volume sampling cup”.9 This involved substituting a small plastic cup for the standard capillary tubing normally used and injecting 100 μl volumes of the diluted samples into the cup using an Oxford automatic pipette (Boehringer Corporation
Ltd) fitted with plastic sampling tips. This method gave an RSD of 2.6% and 4.1% for within batch and between batch precision respectively at a level of 12.6 μmol/l of copper. The copper content of the red blood cell suspensions was also determined as described for whole blood using the stock red blood cell suspension for preparing the calibration graph. Within and between batch precision obtained for these measurements were 3.5% and 5.2% respectively at a level of 5.1 μmol/l of copper.

Validation of results
An internal check on the accuracy of the individual measurements of whole blood and the three blood components analysed was carried out for each blood sample. The values obtained from the white cell, red cell, and plasma measurements were used to obtain a theoretical value for the whole blood. These calculated concentrations were then compared with the directly measured whole blood concentrations and percentage deviations calculated, assuming that the direct determination on whole blood represented 100% recovery of zinc and copper.

Data processing and statistics
Data processing was carried out on an ICL 2970 computer and the appropriate statistics were obtained by using the SPSS package.10

Results
The zinc and copper concentrations in leucocytes, erythrocytes, plasma and whole blood are summarised in Table 1. Table 2 shows the mean concentrations of copper and zinc measured in plasma, red cells and white cells expressed as the amount present per litre of blood, and a comparison of the mean predicted whole blood concentration from the sum of these individual fractions and the concentration obtained by direct analysis of whole blood is also given. Ninety-three per cent of the predicted whole blood zinc concentrations fell within ±3% of the measured values; the greatest difference was a predicted concentration 6% greater than the measured concentration. Similarly, 95% of the predicted whole blood copper concentrations fell within ±5% of the measured values with the largest difference showing a predicted concentration 11% higher than the measured concentration.

Reference ranges
The reference ranges for copper and zinc in whole blood, red cells, white cells and plasma are shown in Table 3. These data were derived from the cumulative frequency distribution curves.

Table 1 Zinc and copper concentrations (mean ± SD) in leucocytes and erythrocytes (per 10⁶ cells), plasma and blood (μmol/l)

<table>
<thead>
<tr>
<th></th>
<th>Leucocyte contents (pmol/10⁶ cells)</th>
<th>Erythrocyte contents (pmol/10⁶ cells)</th>
<th>Plasma (μmol/l)</th>
<th>Whole blood (μmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n = 119</td>
<td>Zinc</td>
<td>116 ± 31</td>
<td>16.6 ± 2.6</td>
<td>12.8 ± 1.9</td>
</tr>
<tr>
<td></td>
<td>Copper</td>
<td>10.9 ± 3.7</td>
<td>1.12 ± 0.17</td>
<td>17.6 ± 4.2</td>
</tr>
<tr>
<td>Men n = 55</td>
<td>Zinc</td>
<td>122 ± 34</td>
<td>16.3 ± 2.4</td>
<td>13.3 ± 2.2</td>
</tr>
<tr>
<td></td>
<td>Copper</td>
<td>11.3 ± 7.1</td>
<td>1.12 ± 0.17</td>
<td>15.5 ± 3.7</td>
</tr>
<tr>
<td>Women n = 64</td>
<td>Zinc</td>
<td>111 ± 27</td>
<td>1.6 ± 2.7</td>
<td>1.5 ± 0.5</td>
</tr>
<tr>
<td></td>
<td>Copper</td>
<td>10.8 ± 3.9</td>
<td>1.13 ± 0.18</td>
<td>19.5 ± 4.7</td>
</tr>
</tbody>
</table>

Table 2 Mean zinc and copper concentrations per litre of blood in plasma, red cells and white cells measured separately and of whole blood, predicted and directly measured

<table>
<thead>
<tr>
<th></th>
<th>Plasma</th>
<th>Red cells</th>
<th>White cells</th>
<th>Predicted whole blood</th>
<th>Measured whole blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc</td>
<td>7.68</td>
<td>80.45</td>
<td>0.69</td>
<td>88.82</td>
<td>88.97</td>
</tr>
<tr>
<td>Copper</td>
<td>10.13</td>
<td>5.96</td>
<td>0.04</td>
<td>16.13</td>
<td>15.17</td>
</tr>
</tbody>
</table>

Units of measurement = μmol/l of whole blood.
No. of subjects = 119
Zinc and copper concentrations in leucocytes and erythrocytes in healthy adults

EFFECTS OF AGE, SEX, AND PILL
The following groups were selected for statistical analysis: male population; female population; women on the pill; women not on the pill. Mean values for red cells, white cells, plasma and whole blood were compared for both zinc and copper.

Table 4 shows the values obtained for women off and on the pill. Women on the pill were found to have significantly higher concentrations of copper in plasma and whole blood than women not on the pill (p < 0.001). However no significant differences in concentrations of zinc were observed for any of the fractions or for whole blood. Since the maximum age of the group of women taking oral contraceptives was 40 yr, the group of women not taking oral contraceptives was further subdivided to provide a group with a comparable age range. Again, no significant differences in zinc concentrations were observed between the two groups whereas the concentrations of copper in plasma and whole blood showed the same significant increase in women on the pill.

A comparison of the elemental concentrations in the various samples for men and women revealed significantly higher concentrations of copper in plasma and whole blood for women (p < 0.001). However these differences were entirely due to the higher concentrations observed for women taking oral contraceptives, as a comparison of men with women not on the pill showed no significant difference for any of the fractions or whole blood. A significant sex-related difference showing men with higher values was noted only for zinc in whole blood (p < 0.001) and this applied to the total female population and not just those women not on the pill.

Association between variables
No significant correlations were found between the leucocyte values and the plasma, whole blood or red cell values. No correlation was shown between age and any of the other variables.

Discussion
The small differences between the calculated and directly measured values for zinc and copper concentrations in whole blood demonstrate good internal control of the separation and analytical techniques employed. Our data for zinc demonstrates that approximately 90% of the blood zinc is associated with the red cells, with plasma contributing about 9%, and that less than 1% of the total blood zinc is associated with the white cells. Despite the low contribution to the total blood zinc concentration, the white cells contain about seven times as much zinc per cell as the red cells. This figure is at variance with previous conflicting reports of the ratio of fifteen times and nine times. Presumably these discrepancies may be attributed to differences in methodology for the various analyses performed.

Table 3  Reference ranges for copper and zinc in plasma, whole blood, red cells and white cells

<table>
<thead>
<tr>
<th></th>
<th>Plasma (μmol/l)</th>
<th>Red cells (μmol/10⁶ cells)</th>
<th>White cells (μmol/10⁶ cells)</th>
<th>Whole blood (μmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total population</td>
<td>9-16</td>
<td>11-5-20</td>
<td>77-163</td>
<td>68-102</td>
</tr>
<tr>
<td>Men + Women not-on-pill</td>
<td>12.5-21.0</td>
<td>8.85-1.4</td>
<td>4.0-20.5</td>
<td>11.0-16.5</td>
</tr>
<tr>
<td>Women on pill</td>
<td>15.5-29.5</td>
<td></td>
<td></td>
<td>14.23.5</td>
</tr>
<tr>
<td>Copper</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total population</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men + Women not-on-pill</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women on pill</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4  Comparison of copper and zinc concentrations (mean ± SD) in blood cells, plasma and whole blood in women on and off pill

<table>
<thead>
<tr>
<th></th>
<th>Leucocyte contents (μmol/l)</th>
<th>Erythrocyte contents (μmol/l)</th>
<th>Plasma (μmol/l)</th>
<th>Whole blood (μmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not on pill</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All women n = 42</td>
<td>Zinc: 107 ± 29</td>
<td>17.3 ± 2.8</td>
<td>12.2 ± 1.6</td>
<td>87.7 ± 8.5</td>
</tr>
<tr>
<td></td>
<td>Copper: 10.7 ± 4.1</td>
<td>1.11 ± 0.16</td>
<td>17.0 ± 2.8</td>
<td>14.8 ± 1.6</td>
</tr>
<tr>
<td>Women &lt;40 yr n = 30</td>
<td>Zinc: 104 ± 22</td>
<td>17.9 ± 2.2</td>
<td>12.3 ± 1.8</td>
<td>88.2 ± 7.8</td>
</tr>
<tr>
<td></td>
<td>Copper: 10.8 ± 4.5</td>
<td>1.16 ± 0.15</td>
<td>16.7 ± 2.8</td>
<td>14.6 ± 1.7</td>
</tr>
<tr>
<td>On pill (18-38 yr)</td>
<td>Zinc: 119 ± 23</td>
<td>15.9 ± 1.5</td>
<td>12.5 ± 1.5</td>
<td>83.1 ± 10.2</td>
</tr>
<tr>
<td>n = 22</td>
<td>Copper: 10.8 ± 3.5</td>
<td>1.17 ± 0.21</td>
<td>24.3 ± 3.7</td>
<td>19.4 ± 2.6</td>
</tr>
</tbody>
</table>
The suitability of the leucocyte separation technique employed in this study and subsequent analysis of zinc in the white cells has been previously discussed. Furthermore the excellent agreement between the calculated and directly measured whole blood values indicate that the results obtained from this study are reliable and validate the conclusions drawn from them.

The data obtained for copper demonstrate that a large proportion (approximately 70%) of the copper in whole blood is present in the plasma with only 0.25% associated with the white cells and the remainder present in the red cells. Leucocytes were shown to contain about ten times as much copper per cell as the erythrocytes, but there are no other reports with which we can compare our data. As a non-Gaussian distribution was found for some of the parameters measured, reference ranges were obtained from the cumulative frequency distribution curves.

Significant increases in plasma copper concentrations were observed for women taking oral contraceptives and these findings are consistent with previous reports. This study also shows raised concentrations of copper in whole blood in women taking oral contraceptives; these observations are consistent with the positive correlation between plasma and whole blood copper. The increased copper concentration in serum and whole blood are most probably the result of an increased synthesis of caeruloplasmin in response to oestrogen. Increased concentrations of caeruloplasmin with oral contraceptive usage have been previously demonstrated.

Studies have shown however that oral contraceptives do not alter the metabolic balance of copper and it is interesting to note that no significant increase was found in the copper content of leucocytes or erythrocytes in the group of women taking oral contraceptives.

The present study did not show any significant effect of oral contraceptives on serum zinc values which does not agree with some earlier reports but which is in general agreement with more recent publications. It is possible that the decrease in oestrogen content of the newer contraceptive pills may be partly responsible for these conflicting observations. Our results for zinc in whole blood, leucocytes and erythrocytes also show no significant difference between the two groups.

Our findings of no statistically significant differences in plasma, red cell or white cell zinc values between the sexes are in agreement with previous reports. The significantly raised concentrations of whole blood zinc found in men (p < 0.001) may presumably be attributed to the significantly higher red cell counts found in the male population. This evidence has been well documented. The lack of any significant sex-related difference for copper in whole blood, red cells and plasma has also been previously reported. No difference was observed between leucocyte copper values for men or women.

The reference ranges for copper and zinc that have been established should provide a suitable basis for clinical studies on patients who have possible body deficiencies of copper and zinc. It is now possible to assess whether the concentration of these trace metals in the leucocytes may provide a more accurate index of body status than other methods currently in use.

We thank Dr HT Delves for his valuable advice and Miss L Snow for typing the manuscript. We are grateful to the Peel Medical Research Trust for financial assistance.

References
Zinc and copper concentrations in leucocytes and erythrocytes in healthy adults


Requests for reprints to: Professor Barbara E Clayton, Department of Chemical Pathology and Human Metabolism, South Laboratory and Pathology Block, Level D, Southampton General Hospital, Tremona Road, Southampton SO9 4XY, England.